Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

Cancer

Volumn 118, Issue 23, 2012, Pages 5819-5822

  Borthakur, Gautam ^a   Kantarjian, Hagop ^a   Patel, Keyur P ^a   Ravandi, Farhad ^a   Qiao, Wei ^a   Faderl, Stefan ^a   Kadia, Tapan ^a   Luthra, Raja ^a   Pierce, Sherry ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

fms like tyrosine kinase receptor; internal tandem duplication mutation; internal tandem duplications; normal karyotype acute myelogenous leukemia; relapse risk

Indexed keywords

TYROSINE KINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FLT3 ITD GENE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; ONCOGENE; OSTEOBLAST; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FMS-LIKE TYROSINE KINASE 3; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; TANDEM REPEAT SEQUENCES;

EID: 84869500537     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27571     Document Type: Article

References (11)

1. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002; 100: 4372-4380. (Pubitemid 35434129)
2. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008; 111: 2776-2784.
3. Kottaridis PD, Gale RE, Frew ME, et al. The presence of an FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001; 98: 1752-1759.
4. Santos FP, Jones D, Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011; 117: 2145-2155.
5. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-1918. (Pubitemid 351620111)
6. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99: 4326-4335. (Pubitemid 34627197)
7. Meshinchi S, Stirewalt DL, Alonzo TA, et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood. 2008; 111: 4930-4933.
8. Chen W, Jones D, Medeiros LJ, Luthra R, Lin P,. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol. 2005; 130: 726-728. (Pubitemid 43906644)
9. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001; 97: 89-94. (Pubitemid 32061246)
10. Cheung AM, Chow HC, Kwong YL, Liang R, Leung AY,. FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice. Leuk Res. 2010; 34: 119-122.
11. Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia. 2006; 20: 1217-1220. (Pubitemid 43905824)